Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Frexalimab · SAR-441344, INX 021

Other · developed by Sanofi

Phase 3 Most advanced trial
SNY Developer
1 Registered trials

What is Frexalimab?

Frexalimab (SAR441344) is an agent given as an intravenous infusion and studied in multiple sclerosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SAR-441344, INX 021, INX 021-56
Drug type
Other
Therapy area
Neurology
Developer
Sanofi (SNY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
WO7SFK0ENJ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06141486 Phase 3 Multiple Sclerosis Active not recruiting SNY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple Sclerosis

More from Sanofi

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the SNY page.

Follow SNY, the company behind Frexalimab

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.